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Abstract
Purpose The ovarian carcinoma subline A2780/C10B
(C10B) is an oxaliplatin resistant clone derived from the
human ovarian carcinoma cell line A2780. The C10B cells
are characterized by mesenchymal phenotype, decreased
platinum uptake and increased glutathione levels (Hector
et al. in Cancer Lett 245:195–204, 2007; Varma et al. in
Oncol Rep 14:925–932, 2005). Na,K-ATPase- subunit
(Na,K-1) functions as a cell–cell adhesion molecule in epi-
thelial cells and is reduced in a variety of carcinoma cells
that show mesenchymal phenotype. The purpose of this
study is to evaluate the relationship between Na,K-
expression and sensitivity to oxaliplatin.
Methods Cell lines used include A2780, C10B, C10B
transfected with Na,K-1 (C10B-Na,K-) and a canine kid-
ney carcinoma cell line MSV-MDCK also transfected with
Na,K-1 (MSV-MDCK- subunit). Cytotoxicity studies
were performed by sulforhodamine-blue assay. The Na,K-
1 and Na,K-1 subunit localization and expression were by
immunoXuorescence microscopy and Western blot analy-
sis. Platinum accumulation measurements were by atomic
absorption spectrophotometry.
Results C10B cells express highly reduced levels of
Na,K-1 subunit. Exogenous expression of Na,K-1 increased
platinum accumulation and sensitized C10B cells to
oxaliplatin. The pharmacological inhibitor of Na,K-ATPase
ouabain did not alter the oxaliplatin accumulation indicat-
ing that Na,K-1 sensitizes cells in a Na,K-ATPase enzyme
activity independent manner. These Wndings were also con-
Wrmed in MSV-MDCK- subunit cells.
Conclusions This study for the Wrst time reveals that
reduced expression of the Na,K-1 protein is associated
with oxaliplatin resistance in cancer cells and demonstrates
a novel role for this protein in sensitizing the cells to oxa-
liplatin. This study suggests a potentially important role for
Na,K-1 in both prognosis and therapy of oxaliplatin resis-
tant malignancies.
Introduction
Platinum drugs are central to many chemotherapy regimens
in cancer treatment. Oxaliplatin is active in many cisplatin
responsive cancers including ovarian [24], and approved
for colon cancer, a cisplatin non-responsive cancer, because
of its unique activity when administered in combination
with 5-Xuorouracil [35]. Like other forms of chemotherapy
while responsive initially, platinum drug treatment can
eventually result in tumor resistance. Resistance to plati-
num drugs, has been extensively studied especially for cis-
platin and is multifactorial in nature [2, 12]. Mechanisms of
platinum drug resistance include drug accumulation deW-
ciencies, intracellular detoxiWcation, increased repair of
DNA-Platinum adducts, increased tolerance to the drug and
alterations in downstream signaling aVecting cell death
pathways [2, 12, 25]. A variety of drug resistant carcinoma
cell models including of human ovarian, colon, bladder and
lung have been used in these studies. Studies from our
laboratory using A2780 human ovarian carcinoma cells
indicated that the mechanisms of oxaliplatin resistance are
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similar to those for cisplatin, and primarily include
decreased drug accumulation and increased detoxiWcation
by conjugation with glutathione [15,  16]. These studies
suggested that reduced DNA-Platinum adduct formation
was a consequence of the reduced drug accumulation [15,
16]. Additionally, recent studies from our laboratory and
those of others using A2780 ovarian carcinoma cells sug-
gest that the extracellular matrix (ECM) may play a role in
the resistance to oxaliplatin and cisplatin [16, 30, 34].
While mechanisms of drug resistance are extensively
studied, factors that sensitize cancer cells to cytotoxic drugs
are less developed and poorly understood. Epithelial to
mesenchymal transition (EMT) is one of the mechanisms
involved in carcinoma cell progression to metastatic and
drug resistant cancer [32]. During this transition, epithelial
cells lose morphology and expression of epithelial markers
such as cytokeratins, and show Wbroblastic phenotype char-
acterized by increased expression of mesenchymal markers
such as vimentin and Wbronectin [13]. In colorectal carci-
noma cell lines KM12L4 and HT-29, induction of EMT
was reported to be associated with oxaliplatin resistance
[36]. The A2780/C10B (C10B) is a clonal subline, selected
for resistance to oxaliplatin from the parental A2780 human
ovarian carcinoma cells [16]. As reported previously [16],
the C10B clone was isolated using limit-dilution procedure
from A2780/C10, an oxaliplatin resistant cell line derived
from A2780 [9] by plating of single cell suspension and
isolating a colony of >50 cells that was expanded. The
C10B cells are spindle shaped and Wbroblast-like in mor-
phology as described in EMT with a lack of epithelial
membrane antigen (EMA), whereas the parental cells
exhibit epithelial phenotype with the presence of EMA
[16]. Consistent with the phenotype, C10B cells have ele-
vated levels of vimentin, and reduced levels of cytokeratins
[16]. AVymetrix gene expression analysis demonstrated
that the C10B cells have high expression of collagen 6,
matrix metalloproteinases and TGF-2 [ 34]. While it is
reported that chemoresistance to paclitaxel induces EMT in
ovarian carcinoma cells [21], this phenomenon is not well
documented in this tumor type for oxaliplatin resistance.
The Na,K-ATPase, also known as the sodium pump is a
plasma membrane bound, oligomeric enzyme localized to
the basolateral plasma membrane in most epithelial cells. It
is composed of two essential, non-covalently bound sub-
units, 1 (Na,K-1) and 1 (Na,K-1). Na,K-1 is the cata-
lytic subunit, whereas Na,K-1 is involved in the
translation, stability and transport of Na,K-1 on the plasma
membrane [27]. Na,K-ATPase transports two K+ in and
three Na+ out at the expense of one molecule of ATP. It not
only maintains intracellular ion homeostasis but is also crit-
ical for the maintenance of polarized phenotype of epithe-
lial cells [26]. Ouabain is a well studied pharmacological
inhibitor of Na,K-ATPase which speciWcally binds to
Na,K- with an IC50 of 10 nM in most human cell types
[19]. Well diVerentiated epithelial cells express high levels
of Na,K-1, whereas poorly diVerentiated carcinoma cells
with mesenchymal phenotype express reduced levels of this
protein [11, 28]. Na,K-1 levels were drastically reduced in
highly motile and invasive carcinoma cell lines [11] and
correlate with their invasiveness and metastatic potential
[18, 28]. Restoration of Na,K-1 in Moloney Sarcoma virus
transformed Madin–Darby canine kidney cells (MSV-
MDCK) suppressed motility, invasion [6, 28] and tumori-
genicity [18]. These studies strongly indicated a functional
link between reduced Na,K-1 expression and cancer pro-
gression.
In this study, we tested the hypothesis that reduced
expression of Na,K-1 in C10B is associated with oxalipla-
tin resistance by evaluating the relationship between oxa-
liplatin sensitivity, Na,K-1 expression, and platinum
accumulation in C10B cells in comparison with the parental
A2780 and C10B cells transfected with Na,K-1 subunit
(C10B-Na,K-). Results presented here reveal that the
resistant C10B cells have reduced expression of Na,K-1.
Exogenous expression of Na,K-1 results in increased oxa-
liplatin uptake and cellular sensitivity to the drug, indepen-
dent of Na,K-ATPase enzyme activity.
Materials and methods
Drugs
Oxaliplatin was a gift from Dr. Paul Juniewicz of SanoW-
Synthelabo (Malvern, PA).
Cell lines
The ovarian carcinoma cell line A2780 was a gift from
Dr. Ozols (Fox Chase Cancer Center, Philadelphia, PA).
The oxaliplatin resistant C10B subline was derived as a sin-
gle cell clone from a previously described A2780/C10 cell
line [9]. A pooled clone of C10B cells stably expressing
Na,K-1 (C10B-Na,K-) was generated by transfecting the
C10B cells with human Na,K-1 cDNA in a mammalian
expression vector with neomycin resistance (pcDNA3.1
from Invitrogen, Carlsbad, CA). C10B cells transfected
with the empty vector (C10B-Vector) were used as a
control. The ovarian carcinoma cell lines and the C10B-
Na,K- cells were maintained in RPMI 1640 supplemented
with 10% heat inactivated fetal bovine serum (FBS) and
1% L-glutamine (Invitrogen, Grand Island, NY). Other cell
lines used in the study included MSV-MDCK cells stably
transfected with pcDNA3.1 vector (MSV-MDCK-vector)
or Na,K-1 (MSV-MDCK- subunit). Generation of these
cell lines has been described previously [28]. These cellsCancer Chemother Pharmacol (2009) 64:1187–1194 1189
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were grown in DMEM with 10% FBS, 1% penicillin and
streptomycin and 200 g/ml neomycin.
Cytotoxicity assays
Cytotoxicity analysis was carried out using sulforhodamine-
blue (SRB) assay as described previously [16]. Cells were
continuously exposed to oxaliplatin for 72 h, Wxed and sub-
jected to the SRB assay. The optical density (OD) was read
at 570 nm (EL309 Automated Microplate Reader, Bio-Tek
Instruments, Winooski, VT) and percent survival was
determined as [OD570 (treated cells)/OD570 (untreated
cells)] £ 100.
Platinum accumulation
Cells were exposed to oxaliplatin (100 M) for 2 h, washed
thoroughly with PBS and total intracellular platinum was
measured as previously described [15]. For this drug
exposed cells were trypsinized and centrifuged into a pellet
and lysed in 0.5 ml of 0.1% Triton X-100 and 0.2% nitric
acid overnight and sonicated for 1 min. Platinum in the cell
lysate was measured by graphite furnace atomic absorption
spectrophotometry with Zeeman background correction
(PE 4100ZL, Norwalk, CT). Protein was measured using
the Bradford assay. In experiments aimed at Na,K-ATPase
inhibition, cells were pretreated with ouabain (50 M) for
15 min prior to oxaliplatin exposure with a continued incu-
bation with ouabain (50 M) also during the exposure to
oxaliplatin.
ImmunoXuorescence
Cells grown on cover slips were Wxed with chilled methanol,
incubated with antibodies against Na,K-1 or Na,K-1 and
stained with Alexa Fluor 488 conjugated goat anti-mouse
antibody (Invitrogen). Samples were excited with an argon
laser, and the light emitted around 519 nm was recorded.
Images were obtained using a confocal microscope Leica
TCS SP5 (Leica Microsystems Inc., Bannockburn, IL).
Reverse transcription and quantitative real-time PCR
Total RNA was isolated from A2780, C10B and C10B-
Na,K- cells using the RNA Aqueous kit (Ambion, Austin,
TX). RNA concentration was measured using the Nanodrop
Spectrophotometer (Thermo Fisher ScientiWc, Waltham,
MA). First strand cDNA was generated from total RNA
using the High Capacity cDNA kit (Applied Biosystems,
Foster City, CA). One microgram of RNA was reverse tran-
scribed to cDNA according to the manufacturer’s protocol.
Quantitative RT-PCR analysis of ATP1B1 was performed
using the ATP1B1 gene speciWc TaqMan MGB assay and
TaqMan universal master mix on an ABI 7900HT System
from Applied Biosystems. The ‘comparative threshold’
method was used to calculate relative gene expression. Val-
ues were normalized against 18S rRNA.
Western blot analysis
Immunoblot analysis was performed as described previ-
ously [28]. Cells were lysed in a buVer containing 20 mM
Tris–HCl, pH 7.4, 100 mM NaCl, 1% Triton X-100, 1 mM
EDTA, 1 mM EGTA, 1 mM sodium glycerolphosphate,
1 mM sodium orthovanadate, 1 mM PMSF, and 5 g/ml
each of antipain, leupeptin and pepstatin. The lysates were
sonicated, and clariWed by centrifugation at 13,000 rpm for
10 min at 4°C. Total protein was estimated from the super-
natants using the Bio-Rad DC reagent (Bio-Rad, Hercules,
CA) as per manufacturer’s instructions. Total protein
(50 g) was resolved on SDS-PAGE and transferred to
nitrocellulose membrane (Schleicher & Schuell, Keene,
NH). Immunoblotting was performed using a primary anti-
body, and HRP-conjugated secondary antibody diluted in
tris-buVered saline containing 5% non-fat dried milk and
0.1% Tween20. The proteins were detected by using the
enhanced chemiluminescence lighting system according to
the manufacturer’s recommendations (PerkinElmer Life
and Analytical Sciences, Boston, MA). The bands from two
independent experiments were quantiWed using GeneTools
software from PerkinElmer, Waltham, MA. Na,K-1 and
Na,K-1 antibodies were a gift from Dr. William James
Ball Jr., University of Cincinnati, Cincinnati. Anti-Wbro-
nectin and E-cadherin antibodies were from BD Biosci-
ences, San Jose, CA. -Actin (Sigma, St. Louis, MO) was
used as a loading control.
Statistical analysis
SigniWcance of diVerences in cytotoxicity and platinum
accumulation was evaluated using Student’s t test (Systat
Software Inc., Richmond, CA).
Results
Expression of Na,K-1 in A2780, C10B and C10B-Na,K- 
cells
A2780 cells express high levels of Na,K-1 compared to
C10B (Fig. 1a). Exogenous expression of Na,K-1 in C10B
cells increased Na,K-1 levels comparable to its expression
in A2780 (Fig. 1a). There was a 50% reduction in Na,K-1
transcript levels in C10B cells compared to A2780 cells
(Fig. 1b) consistent with the reduction at the protein level.
There was no signiWcant change in the Na,K-1 levels in all1190 Cancer Chemother Pharmacol (2009) 64:1187–1194
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these cell lines (Fig. 1a). However, they were similar
between C10B and C10B-Na,K- cells (Fig. 1a). As
expected both Na,K-1 and Na,K-1 were localized to the
plasma membrane in A2780 and C10B-NaK-1 cells
(Fig. 1c). Consistent with the immunoblot analysis, C10B
cells revealed highly reduced levels of Na,K-1 (Fig. 1c).
Morphologically, C10B cells showed a Wbroblastic pheno-
type, whereas, the A2780 were adherent to each other and
showed epithelial like morphology (Fig. 1c). Interestingly,
following Na,K-1 expression C10B cells grew adherent to
each other and appeared morphologically similar to A2780
cells (Fig. 1c). Expression of mesenchymal marker Wbro-
nectin is one of the hallmarks of EMT [17]. Consistent with
the Wbroblastic morphology, the C10B cells expressed high
levels of Wbronectin which was present at a lower level in
parental A2780 cells (Fig. 1a). On the other hand, the
expression of the epithelial marker, E-cadherin was greatly
reduced in C10B cells (Fig. 1a). Although Na,K-1 expres-
sion induced morphological changes there was no change in
the levels of Wbronectin and E-cadherin compared to C10B
cells (Fig. 1b). This result indicates that exogenous expres-
sion of Na,K-1 in these cells did not reverse the EMT.
Increased sensitivity to oxaliplatin in Na,K-1 transfected 
C10B cells
The sensitivity proWles of the parental A2780 cells to oxa-
liplatin along with the resistant C10B, the C10B-Na,K-
and the vector control are shown in Fig. 2a. The C10B-
Na,K- cells (IC50 =1M) were signiWcantly sensitized
to oxaliplatin as compared to the resistant C10B cells
(IC50 =3M) or the vector control (IC50 =2M)
although their sensitivity was not as high as the parental
A2780 cells (IC50 =0 . 2M). The enhanced sensitivity of
C10B-Na,K- cells to oxaliplatin was statistically signiW-
cant compared to C10B cells or the vector transfected
cells (P <0 . 0 1 ) .
Increased drug accumulation in Na,K-1 transfected C10B 
cells
We previously reported that C10B cells are deWcient in
drug accumulation compared to the parental A2780 cells
[16]. Since the C10B-Na,K- cells exhibit increased sen-
sitivity to oxaliplatin compared to the resistant, C10B
cells, we investigated if there was an altered drug accu-
mulation in these cells. C10B-Na,K- cells showed
about sixfold higher platinum accumulation as com-
pared to the C10B or the vector cells (Fig. 2b). This
increase was highly statistically signiWcant (P < 0.001).
The amount of platinum accumulated by C10B-Na,K-
cells was even higher than the parental cells under
identical conditions of treatment (P =0 . 0 0 5 ) .  T h e s e
results suggest that there is a positive correlation
between Na,K-1 expression and increased platinum
accumulation.
Fig. 1 a Immunoblot analysis 
of Na,K-ATPase subunits, Wbro-
nectin, E-cadherin and actin in 
parental A2780, C10B and 
C10B-Na,K- cells. Densito-
metric quantitations are included 
under each panel. b Relative 
mRNA expression using quanti-
tative real-time PCR. c Morpho-
logical characterization and 
localization of Na,K-ATPase 
subunits by phase contrast 
and epiXuorescence microscopy. 
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ConWrmation of the sensitization and drug accumulation 
phenomenon in MSV-MDCK- subunit cells
Sensitization to oxaliplatin by exogenous expression of
Na,K-1 was investigated in another cell line to test
whether this phenomenon is speciWc to ovarian cells or
occurs in other cell type as well. MSV-MDCK cells
expresses low levels of Na,K-1 and are highly invasive
and metastatic (Fig. 3a). Exogenous expression of Na,K-1
in MSV-MDCK cells (MSV-MDCK- subunit) reduced
their motility, invasiveness and tumorigenic potential [28].
Cytotoxicity and platinum accumulation studies indicated
that MSV-MDCK- subunit cells were more sensitive to
oxaliplatin as compared to the parental cells carrying the
vector and do not express this protein (Fig. 3b). Further
studies conWrmed a statistically signiWcant (P < 0.05)
increase in the accumulation of platinum in MSV-MDCK
cells (Fig. 3c) indicating that Na,K-1 expression facilitates
oxaliplatin uptake and increases sensitivity to this drug.
Oxaliplatin accumulation and resulting sensitization 
to oxaliplatin is independent of the pump function 
of Na,K-ATPase
In order to determine whether the Na,K-ATPase enzyme
activity determines the changes in altered drug accumula-
tion, both C10B-Na,K- cells and the MSV-MDCK- sub-
unit cells were treated with ouabain, a pharmacological
inhibitor of Na,K-ATPase. Ouabain at 50 M concentration
that we used in our experiments is known to completely
inhibit Na,K-ATPase activity in human and canine cells
[19]. The results show that there is no signiWcant diVerence
in platinum accumulation in ouabain treated versus
untreated cells (Fig. 4a, b), suggesting that the pump func-
tion of Na,K-ATPase might not be involved in the observed
increases in drug uptake and sensitization to oxaliplatin in
these cells.
Discussion
The exogenous expression of Na,K-1 in the oxaliplatin
resistant C10B cells increased the uptake and cell sensitiv-
ity to the drug. Increased uptake and sensitization of cells to
the drug were independently conWrmed in kidney carci-
noma cells expressing Na,K-1. Our data also suggests that
Na,K-1 expression increases sensitivity to oxaliplatin
independent of Na,K-ATPase pump function. Thus, these
results for the Wrst time reveal that reduced expression of
Na,K-1 protein is associated with oxaliplatin resistance
and that increasing its levels enhances oxaliplatin sensitiv-
ity of carcinoma cells.
Reduced drug accumulation is one of the commonly
described mechanisms for platinum drug resistance in
many studies with a strong correlation between platinum
accumulation and relative resistance as demonstrated in
human hepatoma BEL7404 cells with increasing acquired
resistance to cisplatin [20], and primary bladder cancer cell
lines with intrinsic resistance to cisplatin [23]. While there
is a consensus that drug accumulation is a major determi-
nant of platinum drug sensitivity, the mechanisms involved
in uptake are still not well understood. In addition, much of
the work to date is on the prototype drug cisplatin and rela-
Fig. 2 a Growth inhibition dose response curves for A2780, C10B,
C10B-Na,K- and vector control following a 72 h exposure to oxalipl-
atin. Data represents percent growth as determined by (OD 570 of treated
cells/OD570 of untreated cells) £ 100. Data represent mean § SD,
n =3 .  I C 50’s A2780: 0.2 M; C10B: 3 M; C10B-Na,K-: 1 M and
Vector: 2 M. b Accumulation of Pt in C10B, Vector control, A2780
and C10B-Na,K- following oxaliplatin treatment. Platinum accumu-
lation following exposure to 100 M oxaliplatin for 2 h. Data represent
mean § SD,  n = 3. The ** represent statistically highly signiWcant
diVerence compared to C10B or vector (P <0 . 0 0 1 ) .  T h e  d i Verence
between A2780 and C10B-Na,K- is also statistically signiWcant
(P = 0.005)
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tively fewer reports exist on the uptake of other platinum
analogs including oxaliplatin. In a recent review, Hall et al.
[14] discuss the current evidence for how cisplatin enters
the cells, its potential extrusion out of cells and cellular
changes in resistance including information that is available
for the platinum analogs. Most of the evidence suggests
that cisplatin uptake and possibly of other analogs involves
multiple mechanisms including diVusion, CTR1 copper
inXux transporter mediated uptake (of cisplatin but not oxa-
liplatin) [29], and organic cation transporters (SLC family
members OCT1 and 2) which may be involved in oxalipla-
tin uptake [37]. It was suggested that the potential specia-
tion in various media of platinum analogs that imparts the
charged versus neutral characteristics to these drugs could
in addition dictate which mechanism of transport may play
a major role [14]. In the absence of evidence for changes in
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Fig. 3 a Immunoblot showing levels of Na,K-1 in MSV-MDCK
cells. b Growth inhibition dose response curves for MSV-MDCK vec-
tor and MSV-MDCK--subunit following 72 h exposure to oxalipla-
tin. Data represents percent growth as determined by (OD 570 of treated
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physicochemical properties of membranes accounting for
altered diVusion in resistant cells, the available evidence
only points to alterations in transport proteins [14]. A
potential role for copper eZux transporters ATP7A/7B and
glutathione conjugate pump (GS-X family) in the eZux of
cisplatin and resistance to the drug has been described
[8, 22].
Na,K-ATPase enzyme function mediated transport has
also been suggested as a potential mechanism in cisplatin
uptake [4, 14]. While the experiments with ouabain inhibi-
tion indicated a potential role for Na,K-ATPase in cisplatin
uptake into 2008 human ovarian carcinoma cells and their
cisplatin resistant variant A2780/DDP [4], no diVerences in
Na,K-ATPase activity between cisplatin sensitive and resis-
tant cells have been observed [3]. Their studies suggested
for a Na+-dependent transporter for cisplatin. In separate
experiments primarily aimed at disrupting the sodium
gradient they concluded that it is the sodium gradient
dissipation, which is also resulting from the inhibition of
Na,K-ATPase activity by ouabain that is aVecting the cis-
platin accumulation [3]. In a panel of human small cell lung
cancer (SCLC) and human non-small cell lung cancer
(NSCLC) cell lines all expressing Na,K-ATPase activity,
ouabain inhibition lowered cisplatin accumulation in
NSCLC cell lines, but not in SCLC, suggesting that other
factors distinct from the pump activity may have an impact
on cisplatin uptake into cells [5]. A more recent report con-
nects Na,K-ATPase activity and not ATP-7A and ATP-7B
in cisplatin sensitivity in oral squamous cell carcinoma
cells [1]. At the moment it is unclear what the exact role of
Na,K-ATPase function is in cisplatin uptake, or a role if
there is any for oxaliplatin uptake. In the two cell models
transfected with Na,K-1, we did not observe any change in
platinum uptake following ouabain treatment. In our exper-
iments, by increased expression of Na,K-1 in ovarian car-
cinoma cells, restoration to sensitivity was achieved
partially, but not completely indicating the multi-factorial
nature of resistance such as high levels of glutathione in
C10B cells that we described earlier [16].
The parental A2780 cells are adherent to each other and
show epithelial phenotype. The C10B cells on the other
hand were of mesenchymal phenotype indicating that dur-
ing the selection of oxaliplatin resistance the A2780 cells
have undergone EMT. This is further conWrmed by the
increased levels of Wbronectin in C10B cells (present
study), positivity for vimentin [16] and up-regulated
expression of genes of extracellular matrix, such as matrix
metalloproteinases, integrin alpha and TGF-2 [34], genes
described to be either part of EMT and/or part of the extra-
cellular matrix mediated drug resistance [10]. Interestingly,
although expression of Na,K-1 induced an adherent phe-
notype as revealed by the change in the morphology of
C10B-Na,K-1 cells, there was no change in the levels of
Wbronectin compared to C10B cells. This result suggests
that the reversal of EMT, i.e., mesenchymal to epithelial
transition (MET) has not taken place in these cells at least
at the molecular level. This is also the case with MSV-
MDCK cells expressing Na,K-1. These cells have not
reverted their mesenchymal phenotype but are more adher-
ent to each other, show reduced motility [6, 28] and tumori-
genicity [18]. We and others recently showed that Na,K-1
is a cell–cell adhesion molecule and increases cell–cell con-
tact when expressed in carcinoma cells [7,  31,  33].
Although the mechanism/s by which Na,K-1 increases
sensitivity to oxaliplatin is not known, it is tempting to
speculate that the cell–cell adhesion function of Na,K-1
might be involved in this process. It is possible that cells
that are contact naive are less sensitive to drugs compared
to cells adherent to each other. Future experiments are nec-
essary to unravel mechanisms by which Na,K-1 is increas-
ing the drug uptake and sensitizing cells for oxaliplatin.
However, the current Wndings have immense therapeutic
potential. First, Na,K-1 levels could be used as a bio-
marker for screening patients that would respond better to
platinum based chemotherapy. Secondly, it may be possible
to target the cancer cells which have become drug-insensi-
tive by increasing the levels of Na,K-1 in these cells using
targeted gene therapy approaches. We suggest that ability
to increase the expression of Na,K-1 should have signiW-
cant therapeutic value for treating drug-insensitive malig-
nancies.
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